Immuno-Oncology Clinical Trials Market Size, Share, Demand & Trends Analysis Report 2028

The global Immuno-Oncology Clinical Trials Market accrued earnings worth approximately 5.4 USD Billion in 2020 and is predicted to gain revenue of about 15.6 USD Billion by 2028, is set to record a CAGR of nearly 13.7% over the period from 2021 to 2028. The report offers assessment and analysis of the Immuno-Oncology Clinical Trials Market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue USD Billion.

Request Free Sample

Immuno-oncology Clinical Trials Market: Synopsis

Design and analysis of immuno-oncology clinical trials has been driven by efficiency patterns and toxicity observed in chemotherapy as well as other targeted agents. This, in turn, helps in completely informing clinical trial design as well as guide therapeutic decision making in immuno-oncology. Breakthroughs in immuno-oncology have brought a paradigm shift in cancer therapies and drug development and this is likely to crop up need for carrying out more of immuno-oncology clinical trials. However, there has been a big task for conducting these trials due to rapidly emerging landscape of healthcare industry.

Apart from this, design & analysis of these clinical trials are facing huge challenge in terms of non-proportional hazards patterns translated into Kaplan-Meier curves encompassed by end-points referred as time to event end-points. Furthermore, researchers have devised new immunotherapy strategies for addressing concerns pertaining to failure of immuno-oncology clinical trials, thereby paving way for expansion of immuno-oncology clinical trials market. Moreover, breakthroughs in immuno-oncology clinical trial strategies have resulted in development of effective drugs for treating immuno-oncology disorders.

Furthermore, immune checkpoint inhibitors have strongly impacted oncology domain resulting in spike in clinical trial enrollment for clinical trials supported by rise in its approval by authorities such as FDA. For the record, in 2016, there were over 800 immuno-oncology clinical tests performed and more than 1, 55,000 patients enrolled for clinical trials on myriad kinds of combinations of immuno-oncology drugs.

Immuno-oncology Clinical Trials Market: Growth Drivers

With immunotherapy adding a new dimension to cancer treatment and becoming a major pillar in oncotherapeutics armamentarium, market for Immuno-oncology Clinical Trials is likely to gain traction in years to come. Massive acceptance of targeted drug treatment methods and breakthroughs in immuno-oncology will shape growth sphere of Immuno-oncology Clinical Trials industry in ensuing years. Furthermore, immuno-oncology agents harvest exceptional anti-tumor mechanisms and favorably influence host immune systems, thereby resulting into positive immune responses. Moreover, these aspects have led to optimal integration of immunotherapy into immuno-oncology clinical trials. This is likely to enlarge scope of growth for immuno-oncology clinical trials industry in span of next few years.

Reportedly, immuno-oncology clinical trials contribute nearly over one-third of total oncology clinical trials, thereby playing a major role in impacting returns for immuno-oncology clinical trials market. Rise in incidence of cancer has forced biotech & pharma firms to carry out more immuno-oncology clinical tests, thereby accounting for major chunk of revenue share of immuno-oncology clinical trials market.

Regional Landscape

North American Market To Reach Highest Peak Of Growth By 2028

Expansion of immuno-oncology clinical trials market in North America over forecast timespan can be credited to surge in demand for personalized drugs to be used in new cancer treatments. In addition to this, large budget allocation for cancer research activities by government as well as private firms is expected to lead to increment in number of immuno-oncology clinical trials in sub-continent. This is likely to augment market profitability in region. For the record, North America had accounted for nearly 52% of overall market revenue share in 2020 and is projected to continue its major contributions towards overall market proceeds even in next seven years.

Immuno-Oncology Clinical Trials Market: Report Scope

Competitive Landscape

Some of the leading in the global market include

• Medpace Holdings Inc.
• AstraZeneca plc
• Novartis AG
• Syneous Health
• Exscientia. 

The global Immuno-Oncology Clinical Trials Market is segmented as follows:

By Design

• Observational Trials
• Interventional Trials

By Phase

• Phase I
• Phase IV
• Phase II
• Phase III

By Indication

• Solid Tumors
• Hematological Cancer

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa